These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 27109901)

  • 1. Meaningful interpretation of serum HER2 ECD levels requires clear patient clinical background, and serves several functions in the efficient management of breast cancer patients.
    Wang T; Zhou J; Zhang S; Bian L; Hu H; Xu C; Hao X; Liu B; Ye Q; Liu Y; Jiang Z
    Clin Chim Acta; 2016 Jul; 458():23-9. PubMed ID: 27109901
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preoperative serum HER2 extracellular domain levels in primary invasive breast cancer.
    Lee SB; Lee JW; Yu JH; Ko BS; Kim HJ; Son BH; Gong G; Lee HJ; Kim SB; Jung KH; Ahn JH; Lee W; Sung J; Ahn SH
    BMC Cancer; 2014 Dec; 14():929. PubMed ID: 25491647
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A prospective study to assess the clinical utility of serum HER2 extracellular domain in breast cancer with HER2 overexpression.
    Reix N; Malina C; Chenard MP; Bellocq JP; Delpous S; Molière S; Sevrin A; Neuberger K; Tomasetto C; Mathelin C
    Breast Cancer Res Treat; 2016 Nov; 160(2):249-259. PubMed ID: 27709352
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High circulating HER2 extracellular domain levels correlate with reduced efficacy of an aromatase inhibitor in hormone receptor-positive metastatic breast cancer: a confirmatory prospective study.
    Colomer R; Llombart-Cussac A; Lloveras B; Ramos M; Mayordomo JI; Fernández R; Tusquets I; Gil M; Barnadas A; Constenla M; Gilabert M; Alba E
    Cancer; 2007 Nov; 110(10):2178-85. PubMed ID: 17926331
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Changes over time of extracellular domain of HER2 (ECD/HER2) serum levels have prognostic value in metastatic breast cancer.
    Bramwell VH; Doig GS; Tuck AB; Wilson SM; Tonkin KS; Tomiak A; Perera F; Vandenberg TA; Chambers AF
    Breast Cancer Res Treat; 2009 Apr; 114(3):503-11. PubMed ID: 18437556
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Value of serum human epithelial growth factor receptor 2 extracellular domain and circulating tumor cells in evaluating therapeutic response in advanced gastric cancer].
    Li Y; Peng Z; Zhang X; Gong J; Shen L
    Zhonghua Wei Chang Wai Ke Za Zhi; 2017 Nov; 20(11):1293-1299. PubMed ID: 29178102
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serum HER2 in combination with CA 15-3 as a parameter for prognosis in patients with early breast cancer.
    Di Gioia D; Dresse M; Mayr D; Nagel D; Heinemann V; Stieber P
    Clin Chim Acta; 2015 Feb; 440():16-22. PubMed ID: 25444743
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic and predictive value of HER2 extracellular domain in metastatic breast cancer treated with lapatinib and paclitaxel in a randomized phase III study.
    Finn RS; Gagnon R; Di Leo A; Press MF; Arbushites M; Koehler M
    J Clin Oncol; 2009 Nov; 27(33):5552-8. PubMed ID: 19858400
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic value of baseline serum HER2 extracellular domain level with a cut-off value of 15 ng/mL in patients with breast cancer: a systematic review and meta-analysis.
    Zhang Z; Li C; Fan H; Xiang Q; Xu L; Liu Q; Zhou S; Xie Q; Chen S; Mu G; Cui Y
    Breast Cancer Res Treat; 2018 Dec; 172(3):513-521. PubMed ID: 30159787
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Measurement of Domain-Specific HER2 (ERBB2) Expression May Classify Benefit From Trastuzumab in Breast Cancer.
    Carvajal-Hausdorf DE; Schalper KA; Pusztai L; Psyrri A; Kalogeras KT; Kotoula V; Fountzilas G; Rimm DL
    J Natl Cancer Inst; 2015 Aug; 107(8):. PubMed ID: 25991002
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Utility of serum HER2 extracellular domain assessment in clinical decision making: pooled analysis of four trials of trastuzumab in metastatic breast cancer.
    Lennon S; Barton C; Banken L; Gianni L; Marty M; Baselga J; Leyland-Jones B
    J Clin Oncol; 2009 Apr; 27(10):1685-93. PubMed ID: 19255335
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serum HER2 as a predictive biomarker for tissue HER2 status and prognosis in patients with gastric cancer.
    Shi HZ; Wang YN; Huang XH; Zhang KC; Xi HQ; Cui JX; Liu GX; Liang WT; Wei B; Chen L
    World J Gastroenterol; 2017 Mar; 23(10):1836-1842. PubMed ID: 28348489
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Circulating HER2 extracellular domain and resistance to chemotherapy in advanced breast cancer.
    Colomer R; Montero S; Lluch A; Ojeda B; Barnadas A; Casado A; Massutí B; Cortés-Funes H; Lloveras B
    Clin Cancer Res; 2000 Jun; 6(6):2356-62. PubMed ID: 10873087
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serum levels of HER2 ECD can determine the response rate to low dose oral cyclophosphamide and methotrexate in patients with advanced stage breast carcinoma.
    Sandri MT; Johansson H; Colleoni M; Zorzino L; Passerini R; Orlando L; Viale G
    Anticancer Res; 2004; 24(2C):1261-6. PubMed ID: 15154657
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serum HER2 extracellular domain levels and HER2 circulating tumor cell status in patients with metastatic breast cancer.
    Aurilio G; Sandri MT; Pruneri G; Zorzino L; Botteri E; Munzone E; Adamoli L; Facchi G; Cullurà D; Verri E; Rocca MC; Zurrida S; Iacovelli R; Nolè F
    Future Oncol; 2016 Sep; 12(17):2001-8. PubMed ID: 27255717
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Outcome prediction values of soluble human epidermal growth factor receptor-2 extracellular domain in metastatic breast cancer.
    Shao X; Wang X; Xu X; Feng J; Han M; Zhang H; Chen ZH; Wang S; Zang YM; Huang P; Jin H; Wang X
    Int J Clin Exp Pathol; 2014; 7(3):1108-13. PubMed ID: 24696727
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serum HER2 supports HER2-testing in tissue at the time of primary diagnosis of breast cancer.
    Di Gioia D; Dresse M; Mayr D; Nagel D; Heinemann V; Kahlert S; Stieber P
    Clin Chim Acta; 2014 Mar; 430():86-91. PubMed ID: 24412321
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Human epidermal growth factor receptor 2 (HER2) extracellular domain levels are associated with progression-free survival in patients with HER2-positive metastatic breast cancer receiving lapatinib monotherapy.
    Lipton A; Leitzel K; Ali SM; Carney W; Platek G; Steplewski K; Westlund R; Gagnon R; Martin AM; Maltzman J
    Cancer; 2011 Nov; 117(21):5013-20. PubMed ID: 21456017
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Serum HER2 ECD level and its clinical significance in advanced breast cancer patients with different molecular subtypes].
    Zhou J; Liu Y; Wang T; Zhang H; Du M; Zhang S; Wu S; Song S; Liu B; Zhang H; Jiang Z
    Zhonghua Yi Xue Za Zhi; 2014 May; 94(18):1384-7. PubMed ID: 25142988
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serum Human Epidermal Growth Factor 2 Extracellular Domain as a Predictive Biomarker for Lapatinib Treatment Efficacy in Patients With Advanced Breast Cancer.
    Lee CK; Davies L; Gebski VJ; Lord SJ; Di Leo A; Johnston S; Geyer C; Cameron D; Press MF; Ellis C; Loi S; Marschner I; Simes J; de Souza P
    J Clin Oncol; 2016 Mar; 34(9):936-44. PubMed ID: 26811533
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.